This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
- MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
- Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
- Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
- PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms
- The Advantage of Antibody Cocktails for Targeted Alpha Therapy Depends on Specific Activity
- MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
- Lognormal Distribution of Cellular Uptake of Radioactivity: Monte Carlo Simulation of Irradiation and Cell Killing in 3-Dimensional Populations in Carbon Scaffolds
- Cellular Dosimetry Using the Geant4 Monte Carlo Toolkit
- Reply: Cellular Dosimetry Using the Geant4 Monte Carlo Toolkit
- Cellular Dosimetry of 111In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
- Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences
- CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution S Values for 131I in Spheres of Various Sizes
- Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor
- 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer
- [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma
- Preclinical Pharmacokinetic, Biodistribution, Toxicology, and Dosimetry Studies of 111In-DTPA-Human Epidermal Growth Factor: An Auger Electron-Emitting Radiotherapeutic Agent for Epidermal Growth Factor Receptor-Positive Breast Cancer
- Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells
- Nuclear Localizing Sequences: An Innovative Way to Improve Targeted Radiotherapy
- Dosimetry of Internal Emitters
- Radiobiologic Principles in Radionuclide Therapy
- Isolating Effects of Microscopic Nonuniform Distributions of 131I on Labeled and Unlabeled Cells
- Antitumor Effects and Normal Tissue Toxicity of 111In-Labeled Epidermal Growth Factor Administered to Athymic Mice Bearing Epidermal Growth Factor Receptor-Positive Human Breast Cancer Xenografts
- Microdosimetric Analysis of {alpha}-Particle-Emitting Targeted Radiotherapeutics Using Histological Images
- Bystander effect produced by radiolabeled tumor cells in vivo